Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17826556 | 0.82 | HRH3 (0.51) | NOS1NOS2NOS3HRH3SIGMAR1 | |
| SCHEMBL15829834 | 0.81 | NOS2 (0.44) | NOS1NOS2NOS3HRH3PIK3CD | |
| SCHEMBL15834048 | 0.80 | NOS3 (0.36) | NOS1NOS2NOS3HRH3SMYD3 | |
| SCHEMBL19159781 | 0.78 | NOS3 (0.42) | NOS1NOS2NOS3HRH3HRH4 | |
| SCHEMBL16217384 | 0.77 | NOS1 (0.36) | NOS1NOS2HRH3PIK3CDHRH4 | |
| SCHEMBL19805953 | 0.77 | NOS3 (0.47) | NOS1NOS2NOS3HRH3SMYD3 | |
| SCHEMBL805472 | 0.76 | NOS3 (0.53) | NOS1NOS2NOS3SMYD3POLB | |
| SCHEMBL17303520 | 0.75 | HCRTR1 (0.39) | NOS1NOS2NOS3HRH3SMYD3 | |
| SCHEMBL20890563 | 0.73 | NOS3 (0.47) | NOS1NOS2NOS3HRH3SMYD3 | |
| SCHEMBL726956 | 0.73 | CYP2C19 (0.51) | NOS1NOS2HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | NOS1 466/4885NOS2 481/4885NOS3 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.